[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cordis US Corp.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100618997","post-market-clinical-follow-up-of-smart-family-of-stents-in-treating-iliac-and-femoropopliteal-artery-disease-100618997",false,"NCT07338890","Post-Market Clinical Follow-Up of S.M.A.R.T. Family of Stents in Treating Iliac and Femoropopliteal Artery Disease","Post-Market Clinical Follow-Up Study of the S.M.A.R.T.™ Nitinol Stent System, S.M.A.R.T.™ CONTROL™ Nitinol Stent System and S.M.A.R.T. ™ Flex Vascular Stent System in the Treatment of Iliac and Femoropopliteal Artery Disease (REAL-SMART)","REAL-SMART","Inclusion Criteria: For data mining purposes, the following criteria will apply in determining which subjects to include in the study:\n\n* Subjects treated with SMART 120\u002F150, SMART CONTROL or SMART Flex according to the respective Instructions for Use for treatment in the iliac, superficial femoral and\u002For proximal popliteal arteries.\n* If an EC-approved informed consent waiver is not obtained, then documented informed consent from the subject or legal representative granting permission to share the subject's clinical data It is recommended to include subjects with follow-up data available for a minimum of five (5) years from the date of treatment\u002Fprocedure or until time of death, whichever came first.\n\nIt is recommended to include subjects with follow-up data available for a minimum of five (5) years from the date of treatment\u002Fprocedure or until time of death, whichever came first. Subjects not included because follow-up information is unavailable will be documented, wherever possible, with respect to demographics and presenting disease state to determine whether they are similar to subjects with follow-up that are enrolled.\n\nExclusion Criteria: For data mining purposes, the following criteria will apply in determining which subjects to exclude in the study:\n\n* Women who were pregnant or lactating at the time of the procedure.\n* Pediatric subjects (\\\u003C18 years of age) at the time of the procedure.","ALL","18 Years",{"count":20,"type":21},240,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate long-term safety and performance per the intended use of the S.M.A.R.T.™ Nitinol Stent System (SMART 120\u002F150), S.M.A.R.T.™ CONTROL™ Nitinol Stent System (SMART CONTROL) and S.M.A.R.T.™ Flex Vascular Stent System (SMART Flex) in the treatment of iliac and femoropopliteal artery disease.",[25,26,27],"Superficial Femoral Artery Stenosis","Iliac Artery Stenosis","Popliteal Artery Stenosis",[25,26,27,29,30,31,32,33],"SMART CONTROL Nitinol Stent System","SMART FLEX Vascular Stent System","SMART Nitinol Stent System","SFA Stenosis","PPA Stenosis","NOT_YET_RECRUITING","2026-01-04",{"date":37,"type":38},"2026-01-14","ACTUAL",{"date":40,"type":21},"2026-01-31",{"date":42,"type":21},"2026-05-30",{"name":44,"class":45},"Cordis US Corp.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100602362","post-approval-study-of-palmaz-mullins-xd-in-treating-pulmonary-artery-stenosis-100602362","NCT07122518","Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis","A Post-Approval Evaluation of the PALMAZ MULLINS XD™ Pulmonary Stent in the Treatment of Pulmonary Artery Stenosis (REALPASS)","REALPASS","\\- Subjects \\*should\\* meet criteria as per the list of indications\u002Fcontraindications in the Instructions for Use, though all subjects treated with PALMAZ MULLINS XD™ Pulmonary Stent will be considered eligible and enrolled.","21 Years",{"count":57,"type":21},75,"The purpose of the clinical investigation is to characterize clinical outcomes and to assess the real-world use of the commercial PALMAZ MULLINS XD™ Pulmonary Stent.",[60],"Pulmonary Artery Stenosis",[62,63,64],"pulmonary artery stenosis","Pulmonary Artery Stenting","PALMAZ MULLINS XD Pulmonary Stent","2025-08-07",{"date":67,"type":38},"2025-08-14",{"date":69,"type":21},"2025-12",{"date":71,"type":21},"2027-12",{"name":44,"class":45},""]